- Record: Senate Floor
- Section type: Floor speeches
- Chamber: Senate
- Date: September 24, 2026
- Congress: 119th Congress
- Why this source matters: This section came from the Senate floor portion of the record.
SENATE RESOLUTION 910—EXPRESSING SUPPORT FOR THE DESIGNATION OF
OCTOBER 2026 AS “LEWY BODY DEMENTIA AWARENESS MONTH”
Mr. BOOKER submitted the following resolution; which was referred to the Committee on Health, Education, Labor, and Pensions:
S. Res. 910
Whereas Lewy body dementia—
(1) affects an estimated 1,400,000 individuals in the
United States;
(2) is the second most common degenerative dementia;
(3) includes dementia with Lewy bodies and Parkinson's
disease dementia; and
(4) is the most expensive form of dementia;
Whereas the symptoms of Lewy body dementia can include
cognitive decline, movement difficulties, visual
hallucinations, fluctuations in alertness, REM-sleep behavior
disorder (RBD), and autonomic dysfunction;
Whereas many people living with Lewy body dementia wait
years for a correct diagnosis which can lead to serious
patient harm and avoidable health care spending;
Whereas there are millions of family members, caregivers,
and friends who provide around-the-clock care and support and
whose lives are greatly affected by Lewy body dementia; and
Whereas more research, education, and support services are
needed for the entire Lewy body dementia community now and in
the future—
(1) to find better treatments and a cure for Lewy body
dementia;
(2) to train healthcare providers and emergency personnel
to recognize Lewy body dementia; and
(3) to facilitate early and accurate diagnosis of Lewy body
dementia: Now, therefore, be it
Resolved, That the Senate—
(1) expresses support for the designation of the month of
October 2026 as “Lewy Body Dementia Awareness Month”;
(2) seeks to increase—
(A) awareness and understanding of Lewy body dementia;
(B) advocates for individuals and families affected by the
disease; and
(C) compassion, dignity, and hope for all those living with
Lewy body dementia;
(3) continues to support research to diagnose Lewy body
dementia and find better treatments and a cure for Lewy body
dementia;
(4) recognizes the individuals living with Lewy body
dementia and their care partners who participate in vital
clinical trials to advance the knowledge of the disease; and
(5) commends the dedication of organizations, volunteers,
researchers, healthcare professionals, and millions of
individuals across the United States working to improve the
quality of life of people living with Lewy body dementia and
their families.